In-vitro evaluation of β-lactamase inhibition by latamoxef and imipenem | Zendy

Albert Sotto | Zendy; Caroline Brunschwig | Zendy; David O’Callaghan | Zendy; M Ramuz | Zendy; Jacques Jourdan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In-vitro evaluation of β-lactamase inhibition by latamoxef and imipenem

Author(s) -

Albert Sotto,

Caroline Brunschwig,

David O’Callaghan,

M Ramuz,

Jacques Jourdan

Publication year - 1996

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/37.4.697

Subject(s) - latamoxef , moxalactam , imipenem , in vitro , microbiology and biotechnology , checkerboard , medicine , antibacterial agent , antibiotics , chemistry , pharmacology , cephalosporin , biology , biochemistry , antibiotic resistance

The in-vitro 50% inhibitory concentrations (IC50s) of latamoxef and imipenem against a set of plasmid-mediated beta-lactamases including TEM-1, TEM-3, TEM-5 and TEM-10 were determined by an enzymatic method using nitrocefin as substrate. The IC50s of both antibiotics against extended-spectrum beta-lactamases were below 0.2 mg/L. The conventional spectrum beta-lactamase TEM-1 was not inhibited by either antibiotic at the highest concentration tested. Except for TEM-10 for which the IC50s of the two antibiotics were the same, imipenem showed significantly greater activity than latamoxef against TEM-3 and TEM-5. Clavulanic acid taken as a control demonstrated greater and wider inhibitory activity, but on the other hand it has no significant antibiotic activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research